Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer
Purpose: The aim of this retrospective, single-center cohort study was to evaluate the effectiveness and safety of two-fraction high-dose-rate brachytherapy (HDR-BT) as monotherapy in a consecutive cohort of prostate cancer patients. Methods: We included consecutive patients who received 28 Gy HDR-B...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Clinical and Translational Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630825000138 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582198801203200 |
|---|---|
| author | Johan Staby Olsén Antonis Valachis Bengt Johansson |
| author_facet | Johan Staby Olsén Antonis Valachis Bengt Johansson |
| author_sort | Johan Staby Olsén |
| collection | DOAJ |
| description | Purpose: The aim of this retrospective, single-center cohort study was to evaluate the effectiveness and safety of two-fraction high-dose-rate brachytherapy (HDR-BT) as monotherapy in a consecutive cohort of prostate cancer patients. Methods: We included consecutive patients who received 28 Gy HDR-BT in two fractions (14 Gy × 2) as monotherapy during 2005 to 2021 at our institution. Eligible patients were derived from an institutional database consisting of prospectively collected data. Primary endpoint was biochemical recurrence (BCR) and secondary endpoints included toxicity (assessed through both healthcare provider and patient-reported outcomes) and quality-of-life (QoL) assessment. Results: In total, 175 patients with prostate cancer (94 % classified as low- or intermediate-risk) were treated with HDR-BT during the study period with a median age of 68 years (range: 51–80), and a median follow-up of 60 months (range: 0–174). The estimated five-year cumulative BCR rate was 3.0 % (95 % Confidence Interval (CI): 0 %–13.3 %) for low-risk patients and 9.6 % (95 % CI: 4.7 %–16.7 %) for intermediate-risk patients. PSA exceeding 10 ng/mL at diagnosis was a significant risk factor for BCR (Odds Ratio (OR) = 3.29, 95 % CI: 1.01–10.67) whereas PSA of ≤0.1 ng/ml as nadir was a significant positive prognostic factor, associated with lower risk of BCR (OR = 0.11, 95 % CI: 0.03–0.33). At 12 months, 22 % of the patients had grade 2 and 3 % grade 3 urinary toxicity whereas 2 % of patients had grade 2 and none grade 3 bowel toxicity. At 12 months, 49 % of the patients with at least some erectile function before the treatment, had an impaired function. Conclusion: We found that two-fraction HDR-BT as monotherapy among patients with mainly low- and intermediate-risk prostate cancer appears to be safe in terms of biochemical recurrence, with a low proportion of severe urinary and bowel toxicity. |
| format | Article |
| id | doaj-art-d375ad19bd1243ef81a26c4e6416a901 |
| institution | Kabale University |
| issn | 2405-6308 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical and Translational Radiation Oncology |
| spelling | doaj-art-d375ad19bd1243ef81a26c4e6416a9012025-01-30T05:14:32ZengElsevierClinical and Translational Radiation Oncology2405-63082025-03-0151100923Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancerJohan Staby Olsén0Antonis Valachis1Bengt Johansson2Department of Oncology, General Hospital of Karlstad, Karlstad, Sweden; Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden; Corresponding author at: Department of Oncology, General Hospital of Karlstad, 65230 Karlstad, Sweden.Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, SwedenDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, SwedenPurpose: The aim of this retrospective, single-center cohort study was to evaluate the effectiveness and safety of two-fraction high-dose-rate brachytherapy (HDR-BT) as monotherapy in a consecutive cohort of prostate cancer patients. Methods: We included consecutive patients who received 28 Gy HDR-BT in two fractions (14 Gy × 2) as monotherapy during 2005 to 2021 at our institution. Eligible patients were derived from an institutional database consisting of prospectively collected data. Primary endpoint was biochemical recurrence (BCR) and secondary endpoints included toxicity (assessed through both healthcare provider and patient-reported outcomes) and quality-of-life (QoL) assessment. Results: In total, 175 patients with prostate cancer (94 % classified as low- or intermediate-risk) were treated with HDR-BT during the study period with a median age of 68 years (range: 51–80), and a median follow-up of 60 months (range: 0–174). The estimated five-year cumulative BCR rate was 3.0 % (95 % Confidence Interval (CI): 0 %–13.3 %) for low-risk patients and 9.6 % (95 % CI: 4.7 %–16.7 %) for intermediate-risk patients. PSA exceeding 10 ng/mL at diagnosis was a significant risk factor for BCR (Odds Ratio (OR) = 3.29, 95 % CI: 1.01–10.67) whereas PSA of ≤0.1 ng/ml as nadir was a significant positive prognostic factor, associated with lower risk of BCR (OR = 0.11, 95 % CI: 0.03–0.33). At 12 months, 22 % of the patients had grade 2 and 3 % grade 3 urinary toxicity whereas 2 % of patients had grade 2 and none grade 3 bowel toxicity. At 12 months, 49 % of the patients with at least some erectile function before the treatment, had an impaired function. Conclusion: We found that two-fraction HDR-BT as monotherapy among patients with mainly low- and intermediate-risk prostate cancer appears to be safe in terms of biochemical recurrence, with a low proportion of severe urinary and bowel toxicity.http://www.sciencedirect.com/science/article/pii/S2405630825000138Prostate cancerHigh-dose-rate brachytherapyMonotherapyEffectivenessToxicity |
| spellingShingle | Johan Staby Olsén Antonis Valachis Bengt Johansson Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer Clinical and Translational Radiation Oncology Prostate cancer High-dose-rate brachytherapy Monotherapy Effectiveness Toxicity |
| title | Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer |
| title_full | Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer |
| title_fullStr | Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer |
| title_full_unstemmed | Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer |
| title_short | Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer |
| title_sort | effectiveness toxicity and impact on quality of life of high dose rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer |
| topic | Prostate cancer High-dose-rate brachytherapy Monotherapy Effectiveness Toxicity |
| url | http://www.sciencedirect.com/science/article/pii/S2405630825000138 |
| work_keys_str_mv | AT johanstabyolsen effectivenesstoxicityandimpactonqualityoflifeofhighdoseratebrachytherapydeliveredintwofractionsasmonotherapyinpatientswithprostatecancer AT antonisvalachis effectivenesstoxicityandimpactonqualityoflifeofhighdoseratebrachytherapydeliveredintwofractionsasmonotherapyinpatientswithprostatecancer AT bengtjohansson effectivenesstoxicityandimpactonqualityoflifeofhighdoseratebrachytherapydeliveredintwofractionsasmonotherapyinpatientswithprostatecancer |